Lyla J. Stanland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lyla J. Stanland has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hazel Xiaohui Ang
Department of Medicine Huddinge Karolinska Institute Huddinge Sweden
73 shared publications - Jacob P. Hoj
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA
73 shared publications - Kris C. Wood
Department of Pharmacology and Cancer Biology, Duke University, Durham, USA
73 shared publications - Micah A. Luftig
Department of Molecular Genetics and Microbiology, Duke University School of Medicine
73 shared publications - Patrick Tan
Cancer and Stem Cell Biology Program, Duke–NUS Graduate Medical School, Singapore, Singapore
73 shared publications - Yunqiang Chu
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore
73 shared publications
Latest Publications
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S3 shows that Dasatinib renders cells hyper-sensitive to BYL719
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S6 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Sequences of guide RNAs used to generate genetic knockouts
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Sequences of guide RNAs used to generate genetic knockouts
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S2 shows ribbon plots generated for non-gastric cancer cell lines included in the screen
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends 1-7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibitor A-1331852 is the only inhibitor capable of increasing BYL719-induced cell death and inhibiting cell growth. S6. CBFB binding co-factor RUNX1 is down-regulated at protein and mRNA level in BYL719 resistant clones. S7. Pan-PIM inhibition or PIM1 KO re-sensitizes CBFB KO and resistant clones to BYL719.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends 1-7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
S1. BYL719 and DMSO beta scores S2. Ribbon plots of non-gastric cancer cell lines included in screen. S3. Dasatinib renders AGS cells hyper-sensitive to BYL719 S4. Loss of BCL-XL induces cell death in BYL719 treated MKN1 S5. BCL-XL inhibitor A-1331852 is the only inhibitor capable of increasing BYL719-induced cell death and inhibiting cell growth. S6. CBFB binding co-factor RUNX1 is down-regulated at protein and mRNA level in BYL719 resistant clones. S7. Pan-PIM inhibition or PIM1 KO re-sensitizes CBFB KO and resistant clones to BYL719.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S9 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Quantification of Human Phospho-Proteome Array
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Quantification of Human Phospho-Proteome Array
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S7 shows loss of PIM1 re-sensitizes resistant cells to BYL719
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S5 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S5 shows BH3 mimetics and MCL1 modifiers in combination with BYL719
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CBF-beta mitigates PI3K-alpha-specific inhibitor killing through PIM1 in PIK3CA mutant gastric cancer
Figure S1 shows BYL719 and DMSO beta scores calculated by the MAGeCK analysis pipeline